Enliven Therapeutics: Innovating Precision Oncology for Enhanced Cancer Treatment

Enliven Therapeutics, based in Boulder, Colorado, is pioneering a precision oncology approach to address unmet needs in cancer treatment. By leveraging deep insights into clinically validated biological targets and innovative chemistry, Enliven aims to develop first-in-class or best-in-class therapies that enhance patient survival and overall well-being.

Forward-Looking Statements

This announcement includes forward-looking statements concerning Enliven’s strategic goals and future plans, as well as expectations for its lead product candidate, ELVN-001. These statements are based on current management beliefs and involve risks and uncertainties that could cause actual outcomes to differ materially. Key risks include Enliven’s limited operational history, challenges in advancing product candidates, obtaining regulatory approvals, and competition within the industry. Enliven is committed to updating its forward-looking statements as required by law.

Clinical Data and Comparisons

Currently, Enliven has not conducted head-to-head trials for ELVN-001. The data referenced is sourced from various clinical trials with differing designs and patient demographics, making direct comparisons challenging.

Contact Information

For investor inquiries, please contact: ir@enliventherapeutics.com

For media inquiries, please contact: media@enliventherapeutics.com

Enliven continues to explore strategic collaborations and opportunities to enhance its pipeline and bring innovative cancer therapies to market.